RxDoctor Payments Data

Michael Kapsokavathis, DO

Orthopaedic Surgery of the Spine · Birmingham, MINPI 1568664134

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $86,534 of the $120,487 with a category attached, or 71.8%. Spineart SA accounts for 71.8% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $31,087 and has fallen 57.2% since, to $13,303 in 2025.

$120,487in general payments, 2019–2025

Across 87 payments — averaging $1384.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Spineart SA$87K
  • Spineart USA Inc$14K
  • SC Medica$8K
  • Precision Spine, Inc.$5K
  • Centinel Spine, LLC$3K
  • Spine Wave, Inc.$1K
  • plus $3K from 11 others

What the payments were for

  • Royalty or licence$86,53472%
  • Consulting fees$6,5005%
  • Travel & lodging$21,26218%
  • Food & beverage$6,1915%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$120,487 in reported general payments places this provider in the 80th percentile of 37 orthopaedic surgery of the spine providers in Michigan.

See all orthopaedic surgery of the spine providers in Michigan

Medicare billing

Part B allowed, 2024
$36,848
Medicare patients
30
Services billed
103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Methocarbamol11$136
Mupirocin13$74

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery of the spine in Birmingham

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →